Ongoing COVID-19 Clinical Trials: A Pharmacological Perspective on Pneumonia

Abstract

COVID-19 is an ongoing global pandemic of coronavirus disease 2019 as an atypical type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV 2). Many potential pharmacological agents are currently being investigated against this disease. This article points to, and justifies, the importance of investigating the potential pharmacotherapies for COVID-19 “pneumonia”, rather than the broad category of COVD-19 disease, or COVID-19 associated acute respiratory distress syndrome (ARDS).